FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to an antitumour therapeutic combination, a pharmaceutical composition containing said combination, and a method of treating a tumour.
EFFECT: combination contains lenvatinib or its pharmaceutically acceptable salt, ifosfamide and etoposide or its pharmaceutically acceptable salt.
10 cl, 3 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING A TUMOUR | 2018 |
|
RU2750539C2 |
| USE OF ERIBULIN AND LENVATINIB AS COMBINATION THERAPY FOR TREATMENT OF CANCER | 2014 |
|
RU2672585C2 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
| METHODS OF TREATING CANCER USING APILIMOD | 2016 |
|
RU2738934C2 |
| METHOD OF TREATMENT BY APPLICATION OF COMBINED THERAPY | 2010 |
|
RU2543348C2 |
| THERAPEUTIC AGENT FOR BILIARY TRACT CANCER TREATMENT | 2016 |
|
RU2728932C2 |
| COMBINATION THERAPIES FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | 2019 |
|
RU2787993C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
